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Background: The current role of intra-operative ultrasound (IOUS) is questioned because of recent
progress in medical imaging. The aim of the present study was to determine the accuracy of IOUS in the
detection of a hepatic tumour (HT) compared with a pre-operative multi-detector computed tomography
(MDCT) scan and magnetic resonance imaging (MRI).
Methods: This retrospective study included 418 patients evaluated using an 8-slice MDCT scan
(SCAN8), 64-slice MDCT scan (SCAN64) and MRI alone or combined with a computed tomography (CT)
scan. The pathological result was used as a gold standard.
Results: Correlation rates for the number of detected lesions compared with pathology results were
0.627 for SCAN8, 0.785 for SCAN64, 0.657 for MRI and 0.913 for IOUS. Compared with pathology, the
rate of concordance was significantly higher with IOUS (0.871) than with SCAN8 (0.736; P = 0.011),
SCAN64 (0.792; P < 0.001) and MRI (0.742; P < 0.001). IOUS was responsible for a change in operative
strategy in 16.5% of patients. Surgery was extended in 12.4%, limited in 1.7% and abandoned in 2.4%.
Conclusions: Compared with cross-sectional pre-operative imaging, IOUS is still superior for the
detection of HT and the planning of surgery. IOUS remains recommended as a routine procedure in
patients having a hepatic resection in the era of modern pre-operative imaging.
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Introduction
The role of liver resection is well established for the management
of metastatic colorectal or neuroendocrine cancers, with 5-year
survival rates after a hepatic resection approaching 50% for col-
orectal liver metastases and up to 76% for neuroendocrine
metastases.1–3 Recently, a hepatic metastasectomy for other solid
tumours such as breast cancer, sarcoma, melanoma, has also been
reported.4,5 Furthermore, the most effective treatment for primary
liver tumours is hepatic resection or liver transplantation.6
A thorough pre-operative evaluation for patients with metastatic
disease confined to the liver or with primary liver tumours is
required to determine which patients can benefit from surgery.
Almost 30 years ago, Makuuchi and Bismuth et al. published
the first papers on the use of intra-operative ultrasonography
(IOUS) for hepatic resections.7–9 However, over the past decades
the quality and speed of pre-operative imaging using a multide-
tector computed tomography (MDCT) scan or magnetic reso-
nance imaging (MRI) have improved dramatically. Helical and
multidetector scanners have had a massive impact on CT scanning
for the detection of lesions defined to the liver.10,11 With the use of
enhanced protocols and contrast agents, MRI has also improved
considerably.12,13 This progress in modern imaging techniques has
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raised questions about the diagnostic validity and accuracy of
IOUS, a method that has also undergone technological refine-
ment. The aim of the present study was to assess the accuracy of
IOUS in the detection of hepatic tumours (HT) compared with
pre-operative CT and MRI.
Materials and methods
This retrospective study, approved by the institutional review
board, included 418 patients with hepatic malignancy operated
consecutively between January 2005 and December 2009.
There were 252 (60.3%) men, the mean age was 61.5 ( 9.8)
years. Two hundred and ninety-seven (71.1%) patients presented
with hepatic metastases from colorectal cancer, 82 (19.6%) with a
primary hepatic tumour (hepatocellular carcinoma or cholangio-
carcinoma) and 39 (9.3%) with another hepatic malignancy.
Patients were evaluated using an 8-slice MDCT scan (SCAN8)
from January 2005 to October 2007, a 64-slice MDCT scan
(SCAN64) from November 2007 to December 2009 and a 1.5-Tesla
MRI (GE Signa MRI system [General Electric Medical Systems,
Milwaukee, WI, USA]) either alone or combined with a MDCT
scan. Contrast-enhanced CT scanning was performed using
Iohexol, 300 mg/ml (Omnipaque 300, GE Healthcare, Princeton,
NJ) which was administered with the use of a power injector at a
rate of 3 ml/s. For patients weighing between 60 and 80 kg, a total
dose of 125 cc was given, for patients weighing between 80 and
105 kg 175 cc was given and for patients weighing more then
105 kg 200 cc was given. Forty-five seconds after the start of the
infusion, entire liver imaging was performed during a breath-hold.
Subsequently, the portal venous phase was obtained at 70 s. Each
image was reconstructed with a contiguous 5-mm-slice thickness.
For MRI, Gadobenate Dimeglumine (Multihance, Bracco Diag-
nostics, Inc., Princeton, NJ, USA)-enhanced imaging of the liver
was performed. Intravenous contrast was power injected at rate of
3 ml/s, and the contrast dosage used was 0.025 mmol/kg (0.1 ml/
kg). Post-contrast sequences were acquired at 30 s, 1-min, 3-min
and 5-min delay.Slice thickness was 7 mm.Patients were instructed
to hold their breath in during image acquisition.
In all patients, an IOUS was performed during surgery. An
IOUS was performed with the ALOKA Ultrasound system (Aloka
Co. Ltd. Tokyo, Japan) with a multifrequency 5–10 MHz trans-
ducer. After a laparotomy, the liver surface was inspected and
palpated by the hepatobiliary surgeon, followed by a thorough
segment-by-segment examination with IOUS. The number, rela-
tionship to segmental portal and hepatic veins and size of all
lesions were evaluated. A change in operative strategy was defined
as a change in the type of resection on the basis of IOUS findings,
compared with the pre-operative planned resection. The pre-
operative strategy was documented at the multidisciplinary
tumour board which takes place several weeks before the opera-
tion. Surgery was classified as similar, extended, limited or can-
celled. The pathological result of resected specimens was used as a
gold standard to evaluate the accuracy of the different imaging
techniques. Version 19.0 of SPSS (SPSS, Inc., Chicago, IL, USA)
was used to provide all statistical analyses. The c2-test, Spearman’s
rank correlation test and the McNemar’s test were used for statis-
tical evaluation.
Results
One hundred and seventy-seven patients (42.3%) were evaluated
using a SCAN8, 180 (43.1%) using a SCAN64 and 205 (49.0%)
using 1.5-Tesla MRI. In 142 patients (34.0%) both a CT scan and
MRI were available (80 patients with SCAN8 and MRI and 62
patients with SCAN64 and MRI). Mean time from pre-operative
imaging to time of the operation was 44.6 (32) days.
The operative procedures are summarized in Table 1.
Number of hepatic tumours
In 24 patients(5.7%), pathology results could not be used as a gold
standard for the number of lesions because a hepatectomy was
combined with radiofrequency ablation or the intervention was
cancelled because of intra-operative findings. Therefore, the accu-
racy of the different imaging techniques for the number of
detected lesions compared with pathology could only be evaluated
in 394 (94.3%) patients. When evaluating the number of tumours
found in these patients, the number of hepatic tumours found on
pathology per patient was 0, 1, 2, 3 and more than 3 for 10, 242, 69,
28 and 45 patients, respectively (Table 2).
Spearman’s rank correlation rates for the number of detected
lesions compared with pathology are shown in Table 3. All corre-
lations were significantly different from 0 (P < 0.010).
The rate of concordance compared with pathology was 0.736
[95% confidence interval (CI): 0.666–0.805] for SCAN8, 0.792
(95% CI: 0.732–0.852) for SCAN64, 0.742 (95% CI: 0.679–0.805)
for MRI and 0.871 (95% CI: 0.837–0.904) for IOUS. Compared
with pathology, the rate of concordance was significantly higher
with IOUS than with SCAN8 (P = 0.011), SCAN64 (P < 0.001)
and MRI (P < 0.001) (Table 4).
Impact on operative strategy
In 86 patients (20.5%), operative strategy was changed intra-
operatively. Of these, 17 (4.0%) patients had a change in operative
strategy as a result of non-IOUS-related intra-operative findings
Table 1 Summary of operative procedures
Surgical procedure Number of
patients (%)
Central hepatectomy 33 (7.9)
Right hepatectomy 124 (29.7)
Extended right hepatectomy 22 (5.3)
Left hepatectomy 73 (17.5)
Extended left hepatectomy 15 (3.6)
Segmentectomy/metastasectomy 137 (32.8)
Hepatectomy cancelled 14 (3.3)
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(i.e. carcinomatosis, cirrhosis, etc.). In 69 patients (16.5%), IOUS
was only responsible for the change in operative strategy (Fig. 1).
In 47 (11.2%) of those patients additional lesions found on IOUS
were responsible for a change in operative strategy. IOUS also had
an impact on the accurate assessment of the proximity to or
invasion of the hepatic vasculature which influenced the operative
strategy in 22 patients (5.3%).
Hepatic resection was extended as a result of IOUS in 52
patients (12.4%). In 37 (8.9%) of those patients additional lesions
were found on IOUS and in 15 (3.5%) patients a change in volume
of the lesion or proximity to or invasion of the hepatic vasculature
was noted on IOUS. In 13 (3.1%) patients the operation was
extended because additional lesions were discovered and/or pal-
pated requiring more extensive surgery. The operation was limited
as a result of IOUS in 7 patients (1,7%) and cancelled in 10
patients (2,4%). In four (1.0%) patients the operation was can-
celled as a result of inspection and/or palpation (carcinomatosis
in three patients and cirrhosis in one patient).
IOUS was responsible for a change in operative strategy in 35
patients (19.8%) with a SCAN8, in 21 patients (11.7%) with a
SCAN64 and in 35 patients (17.1%) with an MRI (Table 5). Inter-
group difference was not significant (P = 0.770).
In 25 patients (6.0%) IOUS differed from pre-operative
imaging but these findings did not result in a change in operative
strategy.
Discussion
Direct surgical exploration of the liver in combination with IOUS
has long been regarded as a gold standard against which any other
result should be tested. For almost 30 years, decision making
during a hepatectomy for primary and secondary hepatic malig-
nancy is influenced by IOUS. In the 1980s and 1990s, a change in
operative strategy as a result of IOUS was noted in 19% to 67% of
patients.14–16 Other historical small series were published proving
IOUS significantly improved detection of hepatic tumours.17–20
However, imaging techniques in the pre-operative assessment of
patients with a hepatic tumour have improved over the years.
Recent sensitivity estimates on a per-patient basis for non-helical
CT, helical CT, MRI and positron emission tomography (PET)
were 60.2%, 64.7%, 75.8% and 94.6%, respectively, and on a per-
lesion basis 52.3%, 63.8%, 64.4% and 75.9%.21 In a recent meta-
analysis, Niekel et al. even found that the sensitivity of MRI
increased significantly after 2004.22 Furthermore, the combination
of PET and CT provides simultaneous functional and anatomic
Table 2 Number of hepatic tumours found per patient
No. of lesions SCAN8 (%) SCAN64 (%) MRI (%) IOUS (%) Pathology (%)
0 2 (1.3) 2 (1.1) 2 (1.1) 10 (2.5) 10 (2.5)
1 104 (65.4) 107 (60.1) 124 (66.7) 242 (61.4) 242 (61.4)
2 30 (18.9) 37 (20.8) 31 (16.7) 69 (17.5) 69 (17.5)
3 15 (9.4) 20 (11.2) 14 (7.5) 29 (7.4) 28 (7.1)
4 6 (3.8) 6 (3.4) 6 (3.2) 30 (7.6) 27 (6.9)
5 1 (0.6) 3 (1.7) 3 (1.6) 7 (1.8) 11 (2.8)
6 0 (0.0) 2 (1.1) 2 (1.1) 5 (1.3) 4 (1.0)
7 1 (0.6) 0 (0.0) 2 (1.1) 1 (0.3) 1 (0.3)
8 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
9 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
10 0 (0.0) 1 (0.6) 2 (1.1) 1 (0.3) 2 (0.5)
Total 159100 178100 186100 394100 394100
MRI, magnetic resonance imaging; IOUS, intra-operative ultrasound.
Table 3 Spearman's rank correlation rates compared with pathology
Imaging Number Correlation rates
SCAN8 159 0.627
SCAN64 178 0.785
MRI 186 0.657
IOUS 394 0.913
Table 4 Comparison of the proportion of concordance (Yes/No) to
pathology for SCAN8, SCAN64 and magnetic resonance imaging
(MRI) vs. intra-opertaive ultrasound (IOUS)
Imaging IOUS McNemar test
No Yes P
SCAN8
No 19 23 0.011
Yes 8 109
SCAN64
No 12 25 <0.001
Yes 4 137
MRI
No 20 28 <0.001
Yes 6 132
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information.23 Because of this recent progress in medical imaging,
the role of IOUS has been questioned.
Within the current series, IOUS changed the operative strategy
in 16.5% of patients. These findings are supported by other
recently published smaller series.24–27
IOUS not only detected lesions not found on pre-operative
investigation in a significant number of patients (47 patients,
11.2%) but also had an impact on the accurate assessment of the
proximity to or invasion of the hepatic vasculature which can
also influence the operative strategy (22 patients, 5.3%). There-
fore, IOUS helps the hepatobiliary surgeon to understand the
three-dimensional relationship between the liver vasculature and
tumour but also improves patient outcome by defining adequate
margins of resection and by selecting the correct type of
resection.
As a result of ethical considerations, the hepatobiliary surgeon
performing IOUS in our series was not blinded to the results of
the pre-operative imaging modalities. This could be considered as
a limitation of the present study. Nevertheless, this study clearly
demonstrated that the use of IOUS is still recommended not only
to confirm the results found on pre-operative imaging, but also to
provide additional information to the surgeon which could
change the surgical strategy intra-operatively.
The present study did not show any intergroup difference
between the pre-operative imaging modalities. This is in contrast
to the results of a recent meta-analysis.22 In this meta-analysis the
authors concluded that MRI was the preferred first-line modality
for evaluating colorectal liver metastases in patients with small
lesions who have not previously undergone therapy. Sensitivity of
MRI was significantly higher compared with the CT scan (P:
0.006). The non-superiority of MRI within the present study may
be explained by the fact that MRI results evaluated in this series
were not achieved from the most recent MRI as it has only been
available at our institution since 2010. In their previous meta-
analysis (which included 0.5-T, 1-T and 1.5-T MRI), Niekel et al.
also found that the sensitivity of MRI performed before 2004
was significantly lower than that for MRI performed after 2004
(P < 0.001). Studies included in this series were achieved from the
1.5-Tesla GE Signa MRI system (General Electric Medical Systems,
Milwaukee, WI) (version 1998 and 2001) which could explain
non-superiority of MRI.
Over the past decade, PET and PET/CT has been increasingly
used for the evaluation of patients with hepatic malignancy. The
introduction of PET/CT has challenged the value of IOUS again.28
As recently shown by Wildi et al., the diagnostic performance of
PET/CT combined with IOUS is higher compared with PET/CT
for patients with colorectal liver metastasis.28 In their series, IOUS
changed the surgical strategy in 35% of patients. However, smaller
lesions often remain undetected in a significant number of
patients and the exact role of FDG PET/CT is not yet clear owing
to the small number of studies.23 Furthermore, most patients
described in the current series were not analysed with PET/CT
and therefore the results of PET/CT were not included for further
analysis.
Yang et al. recently reported that the utility of the pre-operative
helical CT to evaluate colorectal liver metastasis was inversely
Figure 1 Impact on operative strategy
Table 5 Change in operative strategy (OS) according to type of pre-operative imaging
Number of
patients
No change
in OS (%)
Change in OS (%) Limited (%) Abandoned (%) Extended (%)
Total IOUS Total IOUS Total IOUS Total IOUS
SCAN8 177 133 (75.1) 44 (24.9) 35 (19.8) 2 (1.1) 2 (1.1) 9 (5.1) 6 (3.4) 33 (18.6) 27 (15.2)
SCAN64 180 154 (85.6) 26 (14.4) 21 (11.7) 2 (1.1) 2 (1.1) 2 (1.1) 1 (0.6) 22 (12.2) 18 (10.0)
MRI 205 162 (79.0) 43 (21.0) 35 (17.1) 5 (2.4) 5 (2.4) 9 (4.4) 8 (3.9) 29 (14.1) 22 (10.7)
MRI, magnetic resonance imaging; IOUS, intra-operative ultrasound.
668 HPB
HPB 2011, 13, 665–669 © 2011 International Hepato-Pancreato-Biliary Association
proportional to the time interval between imaging and surgery.29
Their model predicted that in order to achieve a sensitivity of over
90%, CT had to be performed no more than 26 days before
surgery. One of the limitations of the present study was that
cross-sectional pre-operative imaging was performed on an
average of 44.6 days from hepatic resection, thus some hepatic
lesions might have become more apparent during this time. In
contrast to the results of Yang et al., no negative impact on accu-
racy for SCAN8, SCAN64 or MRI was found when performed
more than 30 days from the hepatectomy (data not shown).
In conclusion, in spite of the refinement in modern pre-
operative cross-sectional imaging, IOUS remains an important
tool in the operative management of hepatic malignancy. In this
series, IOUS altered the surgical strategy in 16.5% of patients.
Conflicts of interest
None.
References
1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R,
Schulick RD et al. (2002) Trends in long-term survival following
liver resection for hepatic colorectal metastases. Ann Surg 235:759–
766.
2. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD et al.
(2009) Rates and patterns of recurrence following curative intent surgery
for colorectal liver metastasis: an international multi-institutional analysis
of 1669 patients. Ann Surg 250:440–448.
3. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. (1999) Clinical
score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg
230:309–318. discussion 318–321.
4. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M et al. (2006)
Hepatic resection for noncolorectal nonendocrine liver metastases:
analysis of 1,452 patients and development of a prognostic model. Ann
Surg 244:524–535.
5. Vlastos G, Smith DL, Singletary SE, Mirza NQ, Tuttle TM, Popat RJ et al.
(2004) Long-term survival after an aggressive surgical approach in patients
with breast cancer hepatic metastases. Ann Surg Oncol 11:869–874.
6. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF. (2006)
Long-term outcome of resection of large hepatocellular carcinoma. Br J
Surg 93:600–606.
7. Makuuchi M, Hasegawa H, Yamazaki S. (1981) Intraoperative ultrasonic
evaluation for hepatectomy. Jpn J Clin Oncol 11:367–390.
8. Bismuth H, Castaing D. (1984) Peroperative echography in hepatobiliary
surgery. Ann Gastroenterol Hepatol (Paris) 20:221–223.
9. Bismuth H, Castaing D, Kunstlinger F. (1984) Peroperative echography in
hepatobiliary surgery. Presse Med 13:1819–1822.
10. Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK
et al. (2003) Surgically staged focal liver lesions: accuracy and reproduc-
ibility of dualphase helical CT for detection and characterization. Radiol-
ogy 227:752–757.
11. Sahani D, Saini S, Pena C, Nichols S, Prasad SR, Hahn PF et al. (2002)
Using multidetector CT for preoperative vascular evaluation of liver neo-
plasms: technique and results. Am J Roentgenol 179:53–59.
12. Sahani DV, Kalva SP, Tanabe KK, Hayat SM, O'Neill MJ, Halpern EF et al.
(2004) Intraoperative US in patients undergoing surgery for liver neo-
plasms: comparison with MR imaging. Radiology 232:810–814.
13. Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M et al. (2003)
Preoperative evaluation of malignant liver tumors: comparison of unen-
hanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP
and intraoperative US. Eur Radiol 13:262–272.
14. Castaing D, Emond J, Kunstlinger F, Bismuth H. (1986) Utility of operative
ultrasound in the surgical management of liver tumors. Ann Surg
204:600–605.
15. Luck AJ, Maddern G. (1999) Intraoperative abdominal ultrasonography.
Br J Surg 86:5–16.
16. Machi J, Sigel B, Zaren HA, Kurohiji T, Yamashita Y. (1993) Operative
ultrasonography during hepatobiliary and pancreatic surgery. World J
Surg 17:640–645.
17. Rafaelsen SR, Kronborg O, Larsen C, Fenger C. (1995) Intraoperative
ultrasonography in detection of hepatic metastasis from colorectal
cancer. Dis Colon Rectum 38:355–360.
18. Olsen AK. (1990) Intraoperative ultrasonography and the detection of liver
metastasis in patients with colorectal cancer. Br J Surg 77:998–999.
19. Charnley RM, Morris DL, Dennison AR, Hardcastle JD. (1991) Detection
of colorectal liver metastases using intraoperative ultrasonography. Br J
Surg 78:45–48.
20. Machi J, Isomoto H, Kurohiji T. (1991) Accuracy of intraoperative ultra-
sonography in diagnosing liver metastases from colorectal cancer.World
J Surg 15:551–556.
21. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinder-
man AH et al. (2005) Colorectal liver metastases: CT, MR, imaging and
PET for diagnosis-meta-analysis. Radiology 237:123–131.
22. Niekel MC, Bipat S, Stoker J. (2010) Diagnostic imaging of colorectal liver
metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a
meta-analysis of prospective studies including patients who have not
previously undergone treatment. Radiology 257:674–684.
23. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA.
(2004) Does the novel PET/CT imaging modality impact on the treatment
of patients with metastatic colorectal cancer of the liver? Ann Surg
240:1027–1034.
24. Zacherl J, Pokieser P, Wrba F, Scheuba C, Prokesch R, Zacherl M et al.
(2002) Accuracy of multiphasic helical computed tomography and intra-
operative sonography in patients undergoing orthotopic liver transplan-
tation for hepatoma: what is the truth? Ann Surg 235:528–532.
25. Zacherl J, Scheuba C, Imhof M, Zacherl M, Langle F, Pokieser P. (2002)
Current value of intraoperative sonography during surgery for hepatic
neoplasms. World J Surg 26:550–554.
26. Ellsmere J, Kane R, Grinbaum R, Edwards M, Schneider B, Jones D.
(2007) Intraoperative ultrasonography during planned liver resections:
why are we still performing it? Surg Endosc 21:1280–1283.
27. van Vledder MG, Pawlik TM, Munireddy S, Hamper U, de Jong MC, Choti
MA. (2010) Factors determining the sensitivity of intraoperative ultra-
sonography in detecting liver metastases in the modern era. Ann Surg
Oncol 17:2756–2763.
28. Wildi SM, Gubler C, Hany T, Petrowsky H, Clavien PA, Jochum W et al.
(2008) Intraoperative sonography in patients with colorectal cancer and
resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultra-
sound 36:20–26.
29. Yang S, Hongjinda S, Hanna SS, Gallinger S, Wei AC, Kiss A et al. (2010)
Utility of preoperative imaging in evaluating colorectal liver metastasis
over time. HPB 12:605–609.
HPB 669
HPB 2011, 13, 665–669 © 2011 International Hepato-Pancreato-Biliary Association
